Fate Financial Statements From 2010 to 2026

Fate Therapeutics Balance Sheet		Trends
Current Value Last Year Historical Average  10 Year Trend Total Assets 324.5 M 318.9 M 279.8 M Slightly volatile Short and Long Term Debt Total 52.1 M 77.8 M 45.2 M Slightly volatile Other Current Liabilities 20.5 M 28.5 M 17.7 M Slightly volatile Total Current Liabilities 37.2 M 36.1 M 32.2 M Slightly volatile Other Liabilities 4.2 M 4.4 M 9.6 M Pretty Stable Property Plant And Equipment Net 53.8 M 98.5 M 46.4 M Slightly volatile Current Deferred Revenue 361.9 K 381 K 6.4 M Slightly volatile Accounts Payable 4.2 M 2.7 M 3.8 M Slightly volatile Cash 83.5 M 46.6 M 72.2 M Slightly volatile Non Current Assets Total 84.2 M 110.2 M 72.5 M Slightly volatile Non Currrent Assets Other 15.2 M 10.2 M 13.1 M Slightly volatile Other Assets 1.09 1.15 8.8 M Pretty Stable Cash And Short Term Investments 229.7 M 203.7 M 198.1 M Slightly volatile Common Stock Total Equity 115.9 K 110.4 K 59.2 K Slightly volatile Common Stock Shares Outstanding 65 M 118.8 M 56.5 M Slightly volatile Liabilities And Stockholders Equity 324.5 M 318.9 M 279.8 M Slightly volatile Non Current Liabilities Total 66.5 M 75.7 M 60.5 M Slightly volatile Other Current Assets 6.5 M 4.1 M 5.6 M Slightly volatile Total Liabilities 103.7 M 111.8 M 92.7 M Slightly volatile Property Plant And Equipment Gross 176.3 M 167.9 M 57.8 M Slightly volatile Total Current Assets 240.3 M 208.7 M 207.3 M Slightly volatile Short Term Debt 4.8 M 4.6 M 4.2 M Slightly volatile Common Stock 67.2 K 115 K 57.9 K Slightly volatile Property Plant Equipment 212.6 M 202.5 M 68.6 M Slightly volatile Net Tangible Assets 584.4 M 556.5 M 274.8 M Slightly volatile Capital Surpluse 1.7 B 1.7 B 743.5 M Slightly volatile Deferred Long Term Liabilities 5 M 8.3 M 4.3 M Slightly volatile Long Term Debt Total 9.4 M 11.2 M 13.3 M Slightly volatile Short and Long Term Debt 2.7 M 2.8 M 3.6 M Very volatile Non Current Liabilities Other 6.1 M 5.8 M 1.9 M Slightly volatile Net Invested Capital 377.6 M 366.5 M 243.2 M Slightly volatile Net Working Capital 325 M 291.4 M 213 M Slightly volatile Net Receivables 870.2 K 916 K 3.9 M Slightly volatile Capital Stock 103.1 K 134.6 K 84.6 K Slightly volatile Capital Lease Obligations 98.5 M 98.1 M 57.4 M Slightly volatile
Fate Therapeutics Income Statement		Trends
Current Value Last Year Historical Average  10 Year Trend Depreciation And Amortization 5.7 M 9.3 M 4.9 M Slightly volatile Interest Expense 7.1 M 6.7 M 2.9 M Slightly volatile Selling General Administrative 34.7 M 46.5 M 30.1 M Slightly volatile Other Operating Expenses 134.9 M 154.3 M 117 M Slightly volatile Research Development 99.1 M 107.8 M 85.9 M Slightly volatile Cost Of Revenue 12.3 M 12.9 M 37.6 M Pretty Stable Total Operating Expenses 112.8 M 141.4 M 98 M Slightly volatile Interest Income 20.9 M 19.9 M 6.1 M Slightly volatile Reconciled Depreciation 22.9 M 21.8 M 6.8 M Slightly volatile Selling And Marketing Expenses 12.3 M 13.9 M 15.1 M Slightly volatile
Fate Therapeutics Cash Flow Statement		Trends
Current Value Last Year Historical Average  10 Year Trend Stock Based Compensation 22.8 M 24.9 M 19.6 M Slightly volatile Begin Period Cash Flow 82.8 M 46.3 M 71.9 M Slightly volatile Other Cashflows From Financing Activities 9 M 5.5 M 10.6 M Pretty Stable Depreciation 5.7 M 9.3 M 4.9 M Slightly volatile Capital Expenditures 8.7 M 6 M 7.5 M Slightly volatile Total Cash From Financing Activities 5.2 M 5.5 M 82.2 M Pretty Stable End Period Cash Flow 85.4 M 56.9 M 73.9 M Slightly volatile Change To Netincome 62.5 M 59.6 M 23 M Slightly volatile
Financial Ratios		Trends
Current Value Last Year Historical Average  10 Year Trend Price To Sales Ratio 16.68 17.5629 63.4034 Pretty Stable Days Sales Outstanding 52.65 50.307 52.08 Slightly volatile Stock Based Compensation To Revenue 3.94 3.7502 1.3338 Slightly volatile Capex To Depreciation 0.61 0.6405 1.6264 Pretty Stable EV To Sales 21.15 22.2606 53.7088 Very volatile Payables Turnover 5.31 5.59 14.4623 Pretty Stable Sales General And Administrative To Revenue 7.35 6.9998 3.5031 Pretty Stable Research And Ddevelopement To Revenue 17.04 16.2246 8.3255 Pretty Stable Capex To Revenue 0.94 0.8957 0.4044 Slightly volatile Cash Per Share 2.45 1.7144 2.8828 Slightly volatile Days Payables Outstanding 67.32 67.63 72.8058 Slightly volatile Income Quality 0.84 0.7782 0.7712 Pretty Stable Current Ratio 5.46 5.7859 6.4536 Pretty Stable Receivables Turnover 8.0 7.2555 9.3859 Very volatile Capex Per Share 0.079 0.0501 0.0918 Slightly volatile Revenue Per Share 0.0532 0.0559 0.2425 Slightly volatile Interest Debt Per Share 0.55 0.6553 0.6779 Slightly volatile Debt To Assets 0.23 0.2441 0.2334 Slightly volatile Operating Cycle 52.65 50.307 52.08 Slightly volatile Days Of Payables Outstanding 67.32 67.63 72.8058 Slightly volatile Ebt Per Ebit 1.12 0.9229 1.0249 Slightly volatile Quick Ratio 5.46 5.7859 6.4536 Pretty Stable Cash Ratio 1.23 1.2927 3.8686 Slightly volatile Days Of Sales Outstanding 52.65 50.307 52.08 Slightly volatile Free Cash Flow Operating Cash Flow Ratio 0.86 1.0561 1.0559 Very volatile Fixed Asset Turnover 0.0641 0.0674 0.9742 Slightly volatile Debt Ratio 0.23 0.2441 0.2334 Slightly volatile Price Sales Ratio 16.68 17.5629 63.4034 Pretty Stable Asset Turnover 0.0198 0.0208 0.0715 Slightly volatile
Fate Therapeutics Valuation Data		Trends
Current Value Last Year Historical Average  10 Year Trend Market Cap 110.9 M 116.7 M 1 B Pretty Stable Enterprise Value 140.5 M 147.9 M 1 B Pretty Stable

Fate Fundamental Market Drivers

Fate Upcoming Events

About Fate Therapeutics Financial Statements

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Fate Therapeutics is a strong investment it is important to analyze Fate Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Fate Therapeutics' future performance. For an informed investment choice regarding Fate Stock, refer to the following important reports:

How To Invest In Fate Details

Is Fate Stock a good investment? Details

What is Fate Therapeutics' Net Worth? Details

Largest Biotechnology Companies View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies View

Altman Z Score Details

Piotroski F Score Details

Beneish M Score Details

Financial Analysis Details

Buy or Sell Advice Details

Earnings Projections Details